thistle

Silymarin is a natural polyphenolic flavonolignan mixture extracted from the seeds of Silybum marianum. It can inhibit tumor cell proliferation and angiogenesis, and improve insulin resistance, thus being widely used in liver disease-related research and adjuvant applications. Studies have shown that silymarin exhibits inhibitory activity against the SARS-CoV-2 main protease, and it has potential research value in the mechanism-related studies of COVID-19.

Silybin A is the major active constituent of silymarin, a standardized extract of the milk thistle seeds, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silicristin, silidianin and others. Silibinin itself is a mixture of two diastereomers, silybin A and silybin B, in approximately equimolar ratio. Both in vitro and animal research suggest that silibinin has hepatoprotective (antihepatotoxic) properties that protect liver cells against toxins. Silibinin has also demonstrated in vitro anti-cancer effects against human prostate adenocarcinoma cells, estrogen-dependent and -independent human breast carcinoma cells, human ectocervical carcinoma cells, human colon cancer cells, and both small and nonsmall human lung carcinoma cells.

Silibinin-d3 is the deuterium-labelled compound of silibinin, used for isotope tracing. Silibinin is the primary active component of milk thistle, capable of inhibiting cancer cell proliferation and migration.

Silibinin (Standard) is a reference standard for research and analysis in studies involving Silibinin. Silibinin (Silybin) is the major active constituent of silymarin, a standardized extract of the milk thistle seeds, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silicristin, silidianin and others. Silibinin itself is a mixture of two diastereomers, silybin A and silybin B, in approximately equimolar ratio. Both in vitro and animal research suggest that silibinin has hepatoprotective (antihepatotoxic) properties that protect liver cells against toxins. Silibinin has also demonstrated in vitro anti-cancer effects against human prostate adenocarcinoma cells, estrogen-dependent and -independent human breast carcinoma cells, human ectocervical carcinoma cells, human colon cancer cells, and both small and nonsmall human lung carcinoma cells.